The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Australia Army: ASLAV-25 Navy: Armidale-class patrol boats, Hobart-class destroyers, Canberra-class landing helicopter docks Canada Army: Coyote reconnaissance vehicle, LAV VI APC Navy: Harry DeWolf-class offshore patrol vessel Croatia Army: M2 Bradley Georgia Coast Guard: Island-class patrol boat Israel Navy: Super Dvora Mk III-class patrol boat, Shaldag-class fast patrol boat Malaysia Army: ACV-300 IFV New Zealand Army: NZLAV Navy: HMNZS Canterbury multi-role vessel and Protector-class offshore patrol vessels Norway Philippines Army: GKN Simba AIFV, M113 APC Navy: Del Pilar-class offshore patrol vessel, Jacinto-class patrol vessel, Mariano Alvarez-class coastal patrol vessel, and Jose Andrada-class patrol craft Singapore Army: Bionix 25 (replaced by the 30 mm Bushmaster II on the Bionix II), M113A2 Ultra IFV Navy: Endurance-class landing platform dock, Formidable-class frigate Police Coast Guard: New coastal patrol craft (NCPC) Spain Army: VEC-M1 Navy: Meteoro-class offshore patrol vessel Sri Lanka Navy: Hamilton-class cutter, Reliance-class cutter Switzerland Turkey Ukraine Army: Bradley M2A2 ODS & M7 Bradley fire support vehicle,LAV VI Ukrainian Navy: Island-class patrol boat (2019) United States Army: M2/M3 Bradley Navy (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk.
Hard tissue, referring to "normal" calcified tissue, is tissue which is mineralized and has a firm intercellular matrix. The hard tissues of humans are bone, tooth enamel, dentin, and cementum. The term is in contrast to soft tissue.
Pseudoephedrine induces monoamine release in vitro with an EC50Tooltip half maximal effective concentration of 224 nM for norepinephrine and 1,988 nM for dopamine, whereas it is inactive for serotonin. As such, it is about 9-fold selective for induction of norepinephrine release over dopamine release. The drug has negligible agonistic activity at the α1- and α2-adrenergic receptors (Kact >10,000 nM). At the β1- and β2-adrenergic receptors, it acts as a partial agonist with relatively low affinity (β1 = Kact = 309 μM, IATooltip intrinsic activity = 53%; β2 = 10 μM; IA = 47%). It was an antagonist or very weak partial agonist of the β3-adrenergic receptor (Kact = ND; IA = 7%). It is about 30,000 to 40,000 times less potent as a β-adrenergic receptor agonist than (–)-isoproterenol. Pseudoephedrine's principal mechanism of action relies on its action on the adrenergic system. The vasoconstriction that pseudoephedrine produces is believed to be principally an α-adrenergic receptor response. Pseudoephedrine acts on α- and β2-adrenergic receptors, to cause vasoconstriction and relaxation of smooth muscle in the bronchi, respectively. α-Adrenergic receptors are located on the muscles lining the walls of blood vessels. When these receptors are activated, the muscles contract, causing the blood vessels to constrict (vasoconstriction). The constricted blood vessels now allow less fluid to leave the blood vessels and enter the nose, throat, and sinus linings, which results in decreased inflammation of nasal membranes, as well as decreased mucus production.
Alpha particles emitted by polonium ionize air molecules that neutralize charges on the nearby surfaces. Some anti-static brushes contain up to 500 microcuries (20 MBq) of 210Po as a source of charged particles for neutralizing static electricity. In the US, devices with no more than 500 μCi (19 MBq) of (sealed) 210Po per unit can be bought in any amount under a "general license", which means that a buyer need not be registered by any authorities. Polonium needs to be replaced in these devices nearly every year because of its short half-life; it is also highly radioactive and therefore has been mostly replaced by less dangerous beta particle sources. Tiny amounts of 210Po are sometimes used in the laboratory and for teaching purposes—typically of the order of 4–40 kBq (0.11–1.08 μCi), in the form of sealed sources, with the polonium deposited on a substrate or in a resin or polymer matrix—are often exempt from licensing by the NRC and similar authorities as they are not considered hazardous. Small amounts of 210Po are manufactured for sale to the public in the United States as "needle sources" for laboratory experimentation, and they are retailed by scientific supply companies. The polonium is a layer of plating which in turn is plated with a material such as gold, which allows the alpha radiation (used in experiments such as cloud chambers) to pass while preventing the polonium from being released and presenting a toxic hazard. Polonium spark plugs were marketed by Firestone from 1940 to 1953.
Sources: en.wikipedia.org
=== Ryan: The Family Favorite === First aired: 22 March 2009 The victim for the series premier is named Alan, a man who gets bullied by his bigger younger brother. In his tape, Alan explains that Ryan gets away with bullying him because he is the family favorite. He also states that in the past Ryan pushed him down a flight of stairs and put his head through a wall. Another victim named Nick appears in the tape and accuses Ryan of humiliating him and giving him a scar on the forehead by pushing him down some bleachers. Ryan accepts Mayhem's challenge to fight an MMA fighter. Mayhem brings Ryan to his gym and decides to let Ryan punch him in the head (which he describes as annoying but not painful). After watching Ryan in the gym he decides to put Ryan up against Tony 'The Gun' Bonello. Ryan was tapped out three times in the first round; first for a rear naked choke, and then twice more for two consecutive guillotine chokes. In the second round, he was KO'd after a kick in the gut. After the fight Alan and Ryan hug and Ryan apologizes which Alan seems to accept.
== Vertebrates == Tendon cells, or tenocytes, are elongated fibroblast type cells. The cytoplasm is stretched between the collagen fibres of the tendon. They have a central cell nucleus with a prominent nucleolus. Tendon cells have a well-developed rough endoplasmic reticulum and they are responsible for synthesis and turnover of tendon fibres and ground substance.
== History == Charlotte Anderson first published a description of the disorder in 1961, where she observed a seven month old girl who developed intestinal mucosa filled with fat droplets. In 2003, Jones and colleagues identified mutations in the SAR1B gene, which transcripts the SAR1B protein involved in COPII transport and proposed this was the molecular defect of the disorder. To present day, 16 mutations of the SAR1B gene have been discovered. This disease is rare, with only 55 cases diagnosed worldwide.
Sources: en.wikipedia.org
On the other hand, significantly more patients drop off from the antidepressant treatment than from psychotherapy, likely because of the side effects of antidepressants. Successful psychotherapy appears to prevent the recurrence of depression even after it has been terminated or replaced by occasional "booster" sessions. The same degree of prevention can be achieved by continuing antidepressant treatment. Two studies suggest that the combination of psychotherapy and medication is the most effective way to treat depression in adolescents. Both TADS (Treatment of Adolescents with Depression Study) and TORDIA (Treatment of Resistant Depression in Adolescents) showed very similar results. TADS resulted in 71% of their teen subjects having "much" or "very much" improvement in mood over the 61% with medication alone and 43% with CBT alone. Similarly, TORDIA showed a 55% improvement with CBT and drugs versus a 41% with drug therapy alone. However, a more recent meta-analysis of 34 trials of 14 drugs used with children and adolescents found that only fluoxetine produced significant benefit compared to placebo, with a medium-sized effect (standardize mean difference = .5).
=== Other sources === Turquoise prehistoric artifacts (beads) are known since the fifth millennium BCE from sites in the Eastern Rhodopes in Bulgaria – the source for the raw material is possibly related to the nearby Spahievo lead–zinc ore field. In Spain, turquoise has been found as a minor mineral in the variscite deposits exploited during prehistoric times in Palazuelos de las Cuevas (Zamora) and in Can Tintorer, Gavá (Barcelona). China has been a minor source of turquoise for 3,000 years or more. Gem-quality material, in the form of compact nodules, is found in the fractured, silicified limestone of Yunxian and Zhushan, Hubei province. Additionally, Marco Polo reported turquoise found in present-day Sichuan. Most Chinese material is exported, but a few carvings worked in a manner similar to jade exist. In Tibet, gem-quality deposits purportedly exist in the mountains of Derge and Nagari-Khorsum in the east and west of the region respectively. Other notable localities include: Afghanistan; Australia (Victoria and Queensland); north India; northern Chile (Chuquicamata); Cornwall; Saxony; Silesia; and Turkestan.
Their success in so many environments has been attributed to their social organisation and their ability to modify habitats, tap resources, and defend themselves. Their long co-evolution with other species has led to mimetic, commensal, parasitic, and mutualistic relationships. Ant societies have division of labour, communication between individuals, and an ability to solve complex problems. These parallels with human societies have long been an inspiration and subject of study. Many human cultures make use of ants in cuisine, medication, and rites. Some species are valued in their role as biological pest control agents. Their ability to exploit resources may bring ants into conflict with humans, however, as they can damage crops and invade buildings. Some species, such as the red imported fire ant (Solenopsis invicta), Linepithema humile, Wasmannia auropunctata, Anoplolepis gracilipes, and Pheidole megacephala are regarded as invasive species in other parts of the world, establishing themselves in areas where they have been introduced accidentally.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.